Corcept Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.
Did you know?
Generated $672.0 in free cash flow for every $1 of capital expenditure in FY25.
Current Price
$51.42
+10.53%GoodMoat Value
$16.61
67.7% overvaluedProfile
Valuation (TTM)
Market Cap$5.47B
P/E117.20
EV—
P/B8.44
Shares Out106.37M
P/Sales7.11
Revenue$769.10M
EV/EBITDA—
Corcept Therapeutics Inc (CORT) Stock Analysis
Market Cap$5.47B
Current Price$51.42
P/E Ratio117.20
Forward P/E—
PEG Ratio-0.45
EPS$0.82
Book Value$6.09
P/B Ratio8.44
CORT Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 0.8% FCF growth (CAGR)
Cash vs Debt
Net Cash: 114M
Revenue
306M
FY19
354M
FY20
366M
FY21
402M
FY22
482M
FY23
675M
FY24
761M
FY25
Net Income
94M
FY19
106M
FY20
113M
FY21
101M
FY22
105M
FY23
140M
FY24
98M
FY25
CORT 52-Week Range
$32.15
$90.32
50-Day MA: $39.31200-Day MA: $60.70
Did you know?
Profit margin stands at 6.1%.
Corcept Therapeutics Inc (CORT) Financial Summary
Corcept Therapeutics Inc (CORT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $51.42 with a market capitalization of $5.47B.
Key valuation metrics include a P/E ratio of 117.20, price-to-book ratio of 8.44, and EPS of $0.82. The company reports a profit margin of 6.1% and return on equity of 7.2%.
CORT Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $5.47B |
| P/E Ratio | 117.20 |
| EPS | $0.82 |
| P/B Ratio | 8.44 |
| P/S Ratio | 7.11 |
| Profit Margin | 6.1% |
| Return on Equity | 7.2% |
| Debt/Equity | 0.01 |
CORT Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $306.49M | $94.18M |
| FY20 | $353.87M | $106.01M |
| FY21 | $365.98M | $112.51M |
| FY22 | $401.86M | $101.29M |
| FY23 | $482.38M | $105.50M |
| FY24 | $675.04M | $139.73M |
| FY25 | $761.41M | $98.17M |
Corcept Therapeutics Inc (CORT) Valuation
Based on GoodMoat's DCF model, Corcept Therapeutics Inc has a fair value estimate of $16.61. At the current price of $51.42, the stock appears 209.6% overvalued relative to our intrinsic value estimate.
CORT Quality Indicators
Corcept Therapeutics Inc maintains a profit margin of 6.1% and an operating margin of 5.9%. Return on equity stands at 7.2%. The current ratio is 2.92. Debt-to-equity ratio is 0.01.
About Corcept Therapeutics Inc
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.
CORT Free Cash Flow
Corcept Therapeutics Inc generated $141.78M in trailing twelve-month free cash flow, representing an FCF yield of 2.59%. This moderate FCF yield indicates reasonable cash generation.
CORT Shares Outstanding
Corcept Therapeutics Inc has 0.11 billion shares outstanding at a share price of $51.42, giving it a market capitalization of $5.47B.